MedTrace Logo

Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women

NCT00504166 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2013-08-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the changes in bone structure as determined by magnetic resonance imaging measurements among early postmenopausal women after 24 months of treatment with alendronate, 70 mg once a week as compared to placebo

Conditions

Interventions

DRUG

alendronate sodium

alendronate sodium 70 mg tablet once week for 24 months

OTHER

placebo comparator

placebo to match alendronate sodium one tablet once a week for 24 months

Sponsors & Collaborators

Principal Investigators

  • Thomas M Link, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2009-03-31
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00504166 on ClinicalTrials.gov